These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34407911)

  • 1. Exploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy.
    Vincenten SCC; Mul K; Schreuder THA; Voermans NC; Horlings CGC; van Engelen BGM
    Neuromuscul Disord; 2021 Sep; 31(9):824-828. PubMed ID: 34407911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifetime endogenous estrogen exposure and disease severity in female patients with facioscapulohumeral muscular dystrophy.
    Mul K; Horlings CGC; Voermans NC; Schreuder THA; van Engelen BGM
    Neuromuscul Disord; 2018 Jun; 28(6):508-511. PubMed ID: 29655530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The facioscapulohumeral muscular dystrophy - health index: Italian validation of a disease-specific measure of symptomatic burden.
    Carraro E; Greco LC; Lizio A; Beretta M; Pozzi S; Casiraghi J; Becchiati S; Beshiri F; Frisoni MC; Iossa F; Heatwole C; Sansone V
    Disabil Rehabil; 2024 May; 46(10):2130-2137. PubMed ID: 37194629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.
    Statland JM; Shah B; Henderson D; Van Der Maarel S; Tapscott SJ; Tawil R
    Muscle Nerve; 2015 Oct; 52(4):521-6. PubMed ID: 25704033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.
    Goselink RJM; Mul K; van Kernebeek CR; Lemmers RJLF; van der Maarel SM; Schreuder THA; Erasmus CE; Padberg GW; Statland JM; Voermans NC; van Engelen BGM
    Neurology; 2019 Jan; 92(4):e378-e385. PubMed ID: 30568007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.
    Fitzgerald BP; Conn KM; Smith J; Walker A; Parkhill AL; Hilbert JE; Luebbe EA; Moxley RT
    J Neurol; 2016 Dec; 263(12):2528-2537. PubMed ID: 27734165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD).
    Petek LM; Rickard AM; Budech C; Poliachik SL; Shaw D; Ferguson MR; Tawil R; Friedman SD; Miller DG
    Neuromuscul Disord; 2016 Jul; 26(7):405-13. PubMed ID: 27185459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facioscapulohumeral Dystrophy in Childhood: A Nationwide Natural History Study.
    Goselink RJM; Schreuder THA; van Alfen N; de Groot IJM; Jansen M; Lemmers RJLF; van der Vliet PJ; van der Stoep N; Theelen T; Voermans NC; van der Maarel SM; van Engelen BGM; Erasmus CE
    Ann Neurol; 2018 Nov; 84(5):627-637. PubMed ID: 30179273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
    Katz NK; Hogan J; Delbango R; Cernik C; Tawil R; Statland JM
    Brain; 2021 Dec; 144(11):3451-3460. PubMed ID: 34542603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of self-reported symptoms.
    Banerji CRS; Cammish P; Evangelista T; Zammit PS; Straub V; Marini-Bettolo C
    Neuromuscul Disord; 2020 Apr; 30(4):315-328. PubMed ID: 32327287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.
    Eichinger K; Heatwole C; Heininger S; Stinson N; Matichak Stock C; Grosmann C; Wagner KR; Tawil R; Statland JM;
    Muscle Nerve; 2017 Mar; 55(3):333-337. PubMed ID: 27421252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The socioeconomic burden of facioscapulohumeral muscular dystrophy.
    Blokhuis AM; Deenen JCW; Voermans NC; van Engelen BGM; Kievit W; Groothuis JT
    J Neurol; 2021 Dec; 268(12):4778-4788. PubMed ID: 34043041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
    Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE
    BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study.
    Chagarlamudi H; Corbett A; Stoll M; Bibat G; Grosmann C; Matichak Stock C; Stinson N; Shapiro J; Wagner KR
    Muscle Nerve; 2017 Dec; 56(6):1108-1113. PubMed ID: 28214289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based incidence and prevalence of facioscapulohumeral dystrophy.
    Deenen JC; Arnts H; van der Maarel SM; Padberg GW; Verschuuren JJ; Bakker E; Weinreich SS; Verbeek AL; van Engelen BG
    Neurology; 2014 Sep; 83(12):1056-9. PubMed ID: 25122204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-reported reduced sleep quality and excessive daytime sleepiness in facioscapulohumeral muscular dystrophy.
    Hoffmann HM; Malo-Juvera V; Statland JM
    Muscle Nerve; 2022 Oct; 66(4):487-494. PubMed ID: 35893768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facing facial weakness: psychosocial outcomes of facial weakness and reduced facial function in facioscapulohumeral muscular dystrophy.
    van de Geest-Buit WA; Rasing NB; Mul K; Deenen JCW; Vincenten SCC; Siemann I; Lanser A; Groothuis JT; van Engelen BG; Custers JAE; Voermans NC
    Disabil Rehabil; 2023 Jul; 45(15):2507-2516. PubMed ID: 35815498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy.
    Lassche S; Voermans NC; Schreuder T; Heerschap A; Küsters B; Ottenheijm CA; Hopman MT; van Engelen BG
    Muscle Nerve; 2021 Jan; 63(1):60-67. PubMed ID: 32959362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.
    Leung DG; Carrino JA; Wagner KR; Jacobs MA
    Muscle Nerve; 2015 Oct; 52(4):512-20. PubMed ID: 25641525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1.
    Mul K; Voermans NC; Lemmers RJLF; Jonker MA; van der Vliet PJ; Padberg GW; van Engelen BGM; van der Maarel SM; Horlings CGC
    Clin Genet; 2018 Dec; 94(6):521-527. PubMed ID: 30211448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.